Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Public ClinicalTrials.gov record NCT00718523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Study identification
- NCT ID
- NCT00718523
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Translational Research in Oncology
- Other
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Interventions
- AMG 479 Drug
- AMG 479 Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2008
- Primary completion
- Aug 31, 2013
- Completion
- Oct 31, 2014
- Last update posted
- Jan 11, 2016
2009 – 2014
United States locations
- U.S. sites
- 23
- U.S. states
- 9
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Hematology Oncology Medical Group Inc. | Alhambra | California | 91801 | — |
| Providence Saint Joseph Medical Center | Burbank | California | 91505 | — |
| St Jude Heritage Healthcare | Fullerton | California | 92835 | — |
| Wilshire Oncology Medical Group Inc | La Verne | California | 91750 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| UCLA | Los Angeles | California | 90095-1678 | — |
| North Valley Hematology/Oncology Medical Group | Northridge | California | 91325 | — |
| Ventura County Hematology-Oncology Specialists | Oxnard | California | 93030 | — |
| University of California San Francisco | San Francisco | California | 94115 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06510 | — |
| Memorial Cancer Institute | Hollywood | Florida | 33021 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Winship Cancer Institute Emory University School of Medicine | Atlanta | Georgia | 30322 | — |
| Hematology and Oncology Specialists, LLC | Metairie | Louisiana | 70006 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89052 | — |
| Hope A Women's Cancer Center | Asheville | North Carolina | 28806 | — |
| Wake Forest University Baptist Medical Center | Winston-Salem | North Carolina | 27104 | — |
| The Toledo Hospital | Toledo | Ohio | 43606 | — |
| University of Toledo | Toledo | Ohio | 43614 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00718523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00718523 live on ClinicalTrials.gov.